Investment Information

With transparent disclosure of information and communication with markets,
we will grow along with shareholders.

HanAll's Partner HBM Completes First Dosing of Phase 2 of Batoclimab in TED in China


Related Data

HanAll Biopharma (KRX: 009420.KS) announced that its partner Harbour BioMed had completed the first dosing of the first patient in Phase 2 of batoclimab in thyroid eye disease (TED)​ in China. 


For more information, please refer to the link below. 

- HBM's press release link: